ARTICLE | Company News
Serenex, CHDI Inc. deal
January 21, 2008 8:00 AM UTC
Not-for-profit foundation CHDI will assess Serenex's small molecule Hsp90 inhibitors as potential therapeutics for Huntington's disease (HD). Serenex will retain all rights to develop and commerciali...